Skip to content

An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine

An Open-label Observational Safety Study During Administration of Topiramate, for the Prophylaxis of Migraine

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00297336
Enrollment
80
Registered
2006-02-28
Start date
2005-03-31
Completion date
2007-02-28
Last updated
2010-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Disorders

Keywords

Topiramate, Migraine, Headache, Chronic headache, Chronic migraine

Brief summary

A 6-month, observational, post authorization safety study for the collection and evaluation of additional safety data on topiramate as a prophylactic treatment for migraines in adult patients. According to current European and international guidelines the safety and efficacy of drugs will be continuously monitored even after their approval and market circulation.The applicable methods of monitoring include: Observational studies, voluntarily reported adverse events, clinical trials of IV phase and Post Authorization Safety Studies ( PASS). Post Authorization Safety Studies (PASS) during the use of a product are a significant source of information regarding the action of the drug or a therapeutic method under the circumstances of every day clinical practice.

Detailed description

Previous studies have shown that topiramate is effective in preventing migraine headaches. This is a 6-month observational study to evaluate additional safety data of topiramate in the prevention of migraine in adult patients. The study duration is 6-months, with 5 study visits during the study. Administration of topiramate should be according to current Summary of Product Characteristics (SmPC) and daily clinical practice. The decision to prescribe topiramate is decided by the Health Care Professional and it is independent of the protocol. Based on the investigator's judgement, patients who enter the study should fulfill the criteria for administration of prophylactic treatment. In this study a total number of 80 patients with diagnosed migraine according to the criteria of the International Headache Society HIS (Cephalalgia 1998; 8 (Suppl7) :1-98) will participate. Patients who will be enrolled should be either male or female over 18 years of age, fulfilling the above mentioned criteria and who will agree to sign the written informed consent for the anonymous and confidential use of their medical data with their participation in the study. Methods of evaluation include tolerability, laboratory tests, vital signs and Body Weight and Body Mass Index (BMI). Efficacy by assessing migraine attacks, symptomatic medications and Headache Impact Test (HIT-6). Observational study - No investigational drug administered.

Interventions

DRUGTopiramate

80 patients with diagnosed with migraine

Sponsors

Janssen Cilag Pharmaceutica S.A.C.I., Greece
Lead SponsorINDUSTRY

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who meet the IHS (International Headache Society) diagnostic criteria for migraine * Patients who satisfy the migraine prophylactic medication criteria

Exclusion criteria

* Ineligible patient according to the marketed Summary of Product Characteristics of topiramate * Patient with hypersensitivity to topiramate or to some of its components

Design outcomes

Primary

MeasureTime frame
The primary outcome is effectiveness of topiramate based on the frequency of migraine headaches during the monotherapy with topiramate.Visit 1 and visit 5

Secondary

MeasureTime frame
Safety of topiramate (number of SAEs, AEs, Laboratory findings)Visits: 1-5

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026